Linvolseltamab (抗 BCMA x 抗 CD3 二重特異性抗体) と再発/難治性多発性骨髄腫 (LINKER-MM2) の参加者に対するその他のがん治療
再発/難治性多発性骨髄腫患者に対する REGN5458 (抗 BCMA x 抗 CD3 二重特異性抗体) とその他のがん治療の第 1b 相試験
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again.
In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies).
This study is the first time linvoseltamab will be combined with other cancer therapies.
The main goal is to understand if linvoseltamab can be given safely with other cancer treatments, and if so, what dose of linvoseltamab should be used for each combination.
The study is looking at several other research questions, including:
- How many participants treated with linvoseltamab in combination with each of the other cancer treatments have improvement of their multiple myeloma
- What side effects may happen from taking linvoseltamab together with another cancer treatment
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Clinical Trials Administrator
- 電話番号:844-734-6643
- メール:clinicaltrials@regeneron.com
研究場所
-
-
California
-
La Jolla、California、アメリカ、92037
- 募集
- Scripps Clinic Torrey Pines
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30004
- 募集
- Winship Cancer Institute of Emory University
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- 募集
- Indiana University Health Simon Cancer Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Dana Farber/Harvard Cancer Center
-
-
Michigan
-
Detroit、Michigan、アメリカ、48201
- 募集
- Karmanos Cancer Institute
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic
-
-
New York
-
New York、New York、アメリカ、10021
- 募集
- Weill Cornell Medicine/New York Presbyterian Hospital
-
New York、New York、アメリカ、10032
- 募集
- New York Presbyterian Hospital Columbia University Medical Center
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- 募集
- University of North Carolina at Chapel Hill
-
Winston-Salem、North Carolina、アメリカ、27157
- 募集
- Wake Forest University Health Sciences
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- 募集
- The Ohio State University James Cancer Hospital
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- 募集
- University of Texas Southwestern
-
-
Washington
-
Seattle、Washington、アメリカ、98108
- 募集
- VA Puget Sound Health Care System
-
-
-
-
-
Haifa、イスラエル、3109601
- 募集
- Rambam Health Care Campus
-
Jerusalem、イスラエル、91120
- 募集
- Hadassah Medical Center
-
-
Central District
-
Ramat Gan、Central District、イスラエル、5265601
- 募集
- Sheba Medical Center
-
-
-
-
-
Athens、ギリシャ、11528
- 募集
- General Hospital of Athens Alexandra
-
-
Attica
-
Athens、Attica、ギリシャ、10676
- 募集
- Evangelismos General Hospital
-
-
-
-
-
Barcelona、スペイン、08035
- 募集
- Hospital Universitario Vall d'Hebron
-
Barcelona、スペイン、08036
- 募集
- Hospital Clinic de Barcelona
-
Barcelona、スペイン、08908
- 募集
- Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals,
-
Madrid、スペイン、28050
- 募集
- Hospital Universitario HM Sanchinarro
-
Madrid、スペイン、28027
- 募集
- Clinica Universidad de Navarra - Madrid
-
Madrid、スペイン、28006
- 募集
- Universitaru Hospital La Princesa
-
Madrid、スペイン、28041
- 募集
- University Hospital and Research Institute
-
Madrid、スペイン、28034
- 募集
- Hospital Universitario Ramon y Cajal - Servicio de Psiquiatria
-
Salamanca、スペイン、37007
- 募集
- University Hospital of Salamanca
-
-
A Coruna
-
Santiago de Compostela、A Coruna、スペイン、15706
- 募集
- Hospital Clinico Universitario de Santiago
-
-
Barcelona
-
Badalona、Barcelona、スペイン、08916
- 募集
- Hospital Germans Trias i Pujol
-
-
Cantabria
-
Santander、Cantabria、スペイン、39008
- 募集
- Hospital Universitario Marques de Valdecilla
-
-
Madrid
-
Pozuelo de Alarcón、Madrid、スペイン、28223
- 募集
- Hospital Universitario Quiron Salud Madrid
-
-
Navarre
-
Pamplona、Navarre、スペイン、31008
- 募集
- Clinica Universidad de Navarra
-
-
-
-
-
Angers、フランス、49933
- 募集
- Centre Hospitalier Universitaire Angers
-
Montpellier、フランス、34295
- 募集
- CHU Montpellier - Departement D'Hematologie
-
Paris、フランス、75571
- 募集
- Saint Antoine Hospital
-
Villejuif、フランス、94805
- 募集
- Institut Gustave Roussy
-
-
New Aquitaine
-
Poitiers、New Aquitaine、フランス、86021
- 募集
- Centre Hospitalier Universitaire (CHU) de Poitiers
-
-
Nord
-
Lille、Nord、フランス、59037
- 募集
- CHU de Lille - Rue Michel Polonovski
-
-
Pays de la Loire Region
-
Nantes、Pays de la Loire Region、フランス、44093
- 募集
- Nantes University Hospital
-
-
Île-de-France Region
-
Créteil、Île-de-France Region、フランス、94000
- 募集
- Hospital Henri Mondor
-
Paris、Île-de-France Region、フランス、75015
- 募集
- Hopital Necker
-
Paris、Île-de-France Region、フランス、75010
- 募集
- Saint Louis Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
General Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- Participants must have measurable disease as defined in the protocol according to IMWG consensus criteria
- Adequate creatinine clearance, hematologic function and hepatic function, as defined in protocol
- Life expectancy of at least 6 months
Cohort Specific Inclusion Criteria:
For cohorts 1-6, each participant must have RRMM with progression following at least 3 lines of therapy, or at least 2 lines of therapy and either prior exposure to at least 1 anti-CD38 antibody, 1 immunomodulatory imide drug (IMiD) and 1 Proteasome Inhibitor (PI), or double-refractory to 1 PI and 1 IMiD, or the combination of 1 PI and 1 IMiD Cohort 1: Prior treatment with daratumumab is allowed if previously tolerated, as described in the protocol Cohort 2: Prior treatment with carfilzomib is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 3: Prior treatment with lenalidomide is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 4: Prior treatment with bortezomib is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 5: Prior treatment with pomalidomide is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 6: Prior treatment with isatuximab is allowed if previously tolerated, as described in the protocol
Cohort 7 and 8:
- For participants without measurable disease by biochemical parameters [serum or urine M-protein, or serum involved Free Light Chain (FLC)], presence of at least 1 soft tissue plasmacytoma with a single diameter of ≥2 cm
- RRMM with progressive disease and received at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 IMiD, and 1 PI or triple-class refractory disease (anti-CD38 antibody, IMiD, PI) Cohort 9: Progressive RRMM in participants with triple-class refractory disease (anti-CD38 antibody, IMiD, PI) after at least 3 lines of therapy Cohort 10: Progressive RRMM after at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 IMiD, and 1 PI
General Key Exclusion Criteria:
- Diagnosis of plasma cell leukemia, primary light-chain amyloidosis (excluding myeloma associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes)
- Participants with known MM brain lesions or meningeal involvement
- Treatment with any systemic anti-myeloma therapy within 5 half-lives or within 21 days prior to first administration of study drug regimen, whichever is shorter
- History of allogeneic and autologous stem cell transplantation, as described in the protocol
- Unless stated otherwise in a specific sub-protocol, prior treatment with a T cell-based immunotherapy directed against B-Cell Maturation Antigen (BCMA) bispecific antibodies and Bispecific T-cell Engagers (BiTEs), and BCMA Chimeric Antigen Receptor (CAR) T cells (Note: BCMA antibody-drug conjugates are not excluded)
- History of progressive multifocal leukoencephalopathy, neurodegenerative condition or Central Nervous System (CNS) movement disorder or participants with a history of seizure within 12 months prior to study enrollment are excluded
- Live or attenuated vaccination within 28 days prior to first study drug regimen administration with a vector that has replicative potential
- Cardiac ejection fraction <40% by Echocardiogram (Echo) or Multigated Acquisition (MUGA) scan
Cohort Specific Exclusion Criteria:
Cohort 2: Dose expansion: Prior treatment with a BCMA-directed CAR T-cell therapy will not be exclusionary if completed at least 12 weeks prior to first study treatment Cohort 3: Known malabsorption syndrome or pre-existing gastrointestinal (GI) condition that may impair absorption of lenalidomide; delivery of lenalidomide via nasogastric tube or gastrostomy tube is not allowed Cohort 4: Peripheral neuropathy grade ≥2 Cohort 5: Known malabsorption syndrome or pre-existing GI conditions that may impair absorption of pomalidomide; delivery of pomalidomide via nasogastric tube or gastrostomy tube is not allowed
Cohort 7:
- Prior treatment with anti-Lymphocyte Activation Gene 3 (LAG-3) agents. Prior exposure to vaccine therapies or other immune checkpoint modulating therapies such as anti-Programmed cell Death Protein 1 (PD-1) antibodies is permitted, as described in the protocol
- Ongoing or recent (within 2 years) evidence of an autoimmune disease that has required systemic treatment with immunosuppressive agents, as described in the protocol
- Prior solid organ transplant
- History of grade ≥3 immune-mediated adverse events (with the exclusion of endocrinopathies that are fully controlled by hormone replacement) from prior checkpoint inhibitor therapies
Cohort 8:
- Prior treatment with anti-PD-1 or anti-PD-L1 agents. Prior exposure to vaccine therapies or other immune checkpoint modulating therapies such as anti-Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) antibodies is permitted, as described in the protocol
- Encephalitis or meningitis in the year prior to enrollment
- History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to enrollment
- Ongoing or recent (within 2 years) evidence of an autoimmune disease that has required systemic treatment with immunosuppressive agents, as described in the protocol.
- Prior solid organ transplant
- History of grade ≥3 immune-mediated adverse events (with the exclusion of endocrinopathies that are fully controlled by hormone replacement) from prior checkpoint inhibitor therapies
Cohort 9:
- Abnormal QT interval corrected by Fridericia's formula (QTcF), as described in the protocol
- Use of concomitant medications that are known to prolong the QT/QTcF interval including Class Ia and Class III antiarrhythmics at the time of informed consent
- Ongoing use or anticipated use of food or drugs that are known strong/moderate cytochrome P450 (CYP)3A4 inhibitors, or strong CYP3A inducers within 14 days prior to first dose of nirogacestat
- Known malabsorption syndrome or existing gastrointestinal GI condition that may impair absorption of nirogacestat; delivery of nirogacestat via nasogastric tube or gastrostomy tube is not allowed
Cohort 10:
- Known or suspected active Epstein-Barr Virus (EBV) infection
- Known history of Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)
- Prior treatment with cevostamab or another agent with the same target [Fragment crystallizable Receptor-like 5 (FcRH5)]
Dose finding portion: Prior treatment with any BCMA-directed immunotherapy will not be exclusionary, as described in the protocol Dose expansion portion: Prior treatment with any T cell-engaging bispecific antibody directed against BCMA will be exclusionary, as described in the protocol
NOTE: Other protocol defined inclusion/exclusion criteria apply
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Cohort 1: Linvoseltamab + Daratumumab
Linvoseltamab + Daratumumab |
Administered per the protocol
他の名前:
Administered per the protocol
他の名前:
|
|
実験的:Cohort 2: Linvoseltamab + Carfilzomib
Linvoseltamab + Carfilzomib |
Administered per the protocol
他の名前:
Administered per the protocol
他の名前:
|
|
実験的:Cohort 3: Linvoseltamab + Lenalidomide
Linvoseltamab + Lenalidomide |
Administered per the protocol
他の名前:
Administered per the protocol
他の名前:
|
|
実験的:Cohort 4: Linvoseltamab + Bortezomib
Linvoseltamab + Bortezomib |
Administered per the protocol
他の名前:
Administered per the protocol
他の名前:
|
|
実験的:Cohort 5: Linvoseltamab + Pomalidomide
Linvoseltamab + Pomalidomide |
Administered per the protocol
他の名前:
Administered per the protocol
他の名前:
|
|
実験的:Cohort 6: Linvoseltamab + Isatuximab
Linvoseltamab + Isatuximab |
Administered per the protocol
他の名前:
Administered per the protocol
他の名前:
|
|
実験的:Cohort 7: Linvoseltamab + Fianlimab
Linvoseltamab + Fianlimab |
Administered per the protocol
他の名前:
Administered per the protocol
他の名前:
|
|
実験的:Cohort 8: Linvoseltamab + Cemiplimab
Linvoseltamab + Cemiplimab |
Administered per the protocol
他の名前:
Administered per the protocol
他の名前:
|
|
実験的:Cohort 9: Linvoseltamab + Nirogacestat
Linvoseltamab + Nirogacestat |
Administered per the protocol
他の名前:
Administered per the protocol
他の名前:
|
|
実験的:Cohort 10: Linvoseltamab + Cevostamab
Linvoseltamab + Cevostamab |
Administered per the protocol
他の名前:
Administered per the protocol
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
重大な有害事象(SAE)の発生率
時間枠:5年まで
|
5年まで
|
|
|
TEAEの重症度
時間枠:最長5年
|
最長5年
|
|
|
SAEの重症度
時間枠:最長5年
|
最長5年
|
|
|
AESI の重大度
時間枠:最長5年
|
最長5年
|
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
時間枠:Up to 5 Years
|
Up to 5 Years
|
|
|
Incidence of Adverse Events of Special Interest (AESIs)
時間枠:Up to 5 Years
|
Up to 5 Years
|
|
|
Incidence of Dose Limiting Toxicities (DLTs) for each study regimen during the observation period
時間枠:Up to 28 Days
|
Dose finding portion only |
Up to 28 Days
|
|
Incidence of laboratory abnormalities
時間枠:Up to 5 Years
|
≥ grade 3 per National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE v5.0] |
Up to 5 Years
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
全生存期間 (OS)
時間枠:5年まで
|
5年まで
|
|
経時的な血清中の総リンボセルタマブ濃度
時間枠:最長5年
|
最長5年
|
|
Overall Response Rate (ORR) as measured by International Myeloma Working Group (IMWG) criteria
時間枠:Up to 5 Years
|
Up to 5 Years
|
|
Duration of Response (DOR) by IMWG criteria
時間枠:Up to 5 Years
|
Up to 5 Years
|
|
Progression-Free Survival (PFS) as measured by IMWG criteria
時間枠:Up to 5 Years
|
Up to 5 Years
|
|
Rate of Minimal Residual Disease (MRD) negative status by IMWG criteria
時間枠:Up to 5 Years
|
Up to 5 Years
|
|
Incidence over time of Anti-Drug Antibodies (ADAs) to linvoseltamab
時間枠:Up to 5 Years
|
Up to 5 Years
|
協力者と研究者
捜査官
- スタディディレクター:Clinical Trial Management、Regeneron Pharmaceuticals
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 血管疾患
- 心血管疾患
- 新生物
- 免疫系疾患
- 組織型別の新生物
- 血液疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- 新生物、形質細胞
- 止血障害
- パラタンパク血症
- 血液タンパク質障害
- 出血性疾患
- ヘミックおよびリンパ疾患
- 多発性骨髄腫
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- カルボン酸
- ピペリジン
- 無機化学物質
- ボロン酸
- 酸、非カルボン酸
- 酸
- ホウ素化合物
- ピラジン
- フタリミド
- フタル酸
- 酸、炭素環
- ピペリドン
- イソインドール
- レナリドミド
- ボルテゾミブ
- Carfilzomib
- ポマリドマイド
- ダラトゥムマブ
- cemiplimab
- イサトキシブ
- nirogacestat
その他の研究ID番号
- R5458-ONC-2012
- 2020-004638-39 (EudraCT番号)
- 2023 (米国 NIH グラント/契約)
- 2023-506247-42-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD 共有時間枠
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 共有アクセス基準
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。